Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society.

[1]  X. Hou,et al.  Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis , 2020, Journal for ImmunoTherapy of Cancer.

[2]  J. Waterton,et al.  How consistently do physicians diagnose and manage drug-induced interstitial lung disease? Two surveys of European ILD specialist physicians , 2020, ERJ Open Research.

[3]  M. Wahidi,et al.  Transbronchial Cryobiopsy for the Diagnosis of Interstitial Lung Diseases: CHEST Guideline and Expert Panel Report. , 2019, Chest.

[4]  T. Hartman,et al.  Clinical and Histopathologic Features of Immune Checkpoint Inhibitor-related Pneumonitis , 2019, The American journal of surgical pathology.

[5]  W. Travis,et al.  Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor–related Pneumonitis. An Official American Thoracic Society Research Statement , 2019, American journal of respiratory and critical care medicine.

[6]  H. Hatabu,et al.  Imaging of Precision Therapy for Lung Cancer: Current State of the Art. , 2019, Radiology.

[7]  H. Hatabu,et al.  The incidence of ALK inhibitor-related pneumonitis in advanced non-small-cell lung cancer patients: A systematic review and meta-analysis. , 2019, Lung cancer.

[8]  Vinay Prasad,et al.  Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs , 2019, JAMA network open.

[9]  N. M. La‐Beck,et al.  Management of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: a Minireview of Current Clinical Guidelines , 2019, Asia-Pacific journal of oncology nursing.

[10]  A. Yoshimura,et al.  Interstitial Lung Disease Onset and Its Risk Factors in Japanese Patients With ALK‐Positive NSCLC After Treatment With Crizotinib , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  F. Hodi,et al.  Imaging of Cancer Immunotherapy: Current Approaches and Future Directions. , 2019, Radiology.

[12]  R. Sullivan,et al.  Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis , 2018, JAMA oncology.

[13]  Jae Ho Lee,et al.  Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer. , 2018, Lung cancer.

[14]  Y. Yatabe,et al.  Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis. , 2018, Lung cancer.

[15]  I. Bruce,et al.  Drug-Induced Interstitial Lung Disease: A Systematic Review , 2018, Journal of clinical medicine.

[16]  H. Hatabu,et al.  Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC. , 2018, Lung cancer.

[17]  J. Ahn,et al.  Transient Asymptomatic Pulmonary Opacities During Osimertinib Treatment and its Clinical Implication , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[18]  J. Sugisaka,et al.  Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab. , 2018, The oncologist.

[19]  S. Kawachi,et al.  Pre-existing interstitial lung disease as a risk factor for pneumonitis associated with ramucirumab and paclitaxel in patients with gastric cancer: The impact of usual interstitial pneumonia , 2018, PloS one.

[20]  M. Suarez‐Almazor,et al.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Ying Cheng,et al.  Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[22]  Kaoru Tanaka,et al.  Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer , 2017, JAMA oncology.

[23]  M. Suarez‐Almazor,et al.  Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group , 2017, Journal of Immunotherapy for Cancer.

[24]  H. Taavola,et al.  Safety Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre , 2017, Drug Safety.

[25]  H. Hatabu,et al.  Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care. , 2017, Radiographics : a review publication of the Radiological Society of North America, Inc.

[26]  N. Girard,et al.  Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients , 2017, European Respiratory Journal.

[27]  I. Annesi-Maesano,et al.  Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris , 2017, European Respiratory Journal.

[28]  K. Kerr,et al.  Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  F. Hodi,et al.  Monitoring immune-checkpoint blockade: response evaluation and biomarker development , 2017, Nature Reviews Clinical Oncology.

[30]  B. Carneiro,et al.  Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis , 2017, Cancer management and research.

[31]  F. Hodi,et al.  Drug-Related Pneumonitis in the Era of Precision Cancer Therapy. , 2017, JCO precision oncology.

[32]  P. Mazzone,et al.  Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death‐Ligand 1 Inhibitors in Non‐Small Cell Lung Cancer: A Systematic Review and Meta‐Analysis of Trials , 2017, Chest.

[33]  M. Kiehl,et al.  New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management , 2017, Critical Care.

[34]  C. Rudin,et al.  Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  T. McLoud,et al.  A Review of Clinical and Imaging Findings in Eosinophilic Lung Diseases. , 2017, AJR. American journal of roentgenology.

[36]  H. Kenmotsu,et al.  High incidence of interstitial lung disease following practical use of osimertinib in patients who had undergone immediate prior nivolumab therapy. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  T. Morimoto,et al.  Characteristics and Prognostic Impact of Pneumonitis during Systemic Anti-Cancer Therapy in Patients with Advanced Non-Small-Cell Lung Cancer , 2016, PloS one.

[38]  R. Camidge,et al.  Transient Asymptomatic Pulmonary Opacities Occurring during Osimertinib Treatment , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[39]  A. Giobbie-Hurder,et al.  Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis. , 2016, JAMA oncology.

[40]  M. Postow,et al.  Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review. , 2016, JAMA oncology.

[41]  F. Hodi,et al.  PD-1 Inhibitor–Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course , 2016, Clinical Cancer Research.

[42]  N. Kadowaki,et al.  Impact of idiopathic pulmonary fibrosis on advanced non-small cell lung cancer survival , 2016, Journal of Cancer Research and Clinical Oncology.

[43]  R. Hubbard,et al.  In-Hospital Mortality after Surgical Lung Biopsy for Interstitial Lung Disease in the United States. 2000 to 2011. , 2016, American journal of respiratory and critical care medicine.

[44]  G. Cappelli,et al.  Interstitial Lung Disease After Kidney Transplantation and the Role of Everolimus. , 2016, Transplantation proceedings.

[45]  P. Jänne,et al.  Anti–PD-1 Inhibitor–Related Pneumonitis in Non–Small Cell Lung Cancer , 2016, Cancer Immunology Research.

[46]  H. Hatabu,et al.  Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy in patients with neuroendocrine tumors: a radiographic pattern-based approach. , 2016, European journal of cancer.

[47]  M. Ahn,et al.  459PRisk of pneumonitis in patients with advanced NSCLC treated with pembrolizumab in KEYNOTE-001 , 2015 .

[48]  H. Hatabu,et al.  Drug-Related Pneumonitis During Mammalian Target of Rapamycin Inhibitor Therapy: Radiographic Pattern-Based Approach in Waldenström Macroglobulinemia as a Paradigm. , 2015, The oncologist.

[49]  F. Hodi,et al.  Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy. , 2015, The New England journal of medicine.

[50]  D. Carbone,et al.  Non–Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[51]  F. Hodi,et al.  Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab , 2015, Cancer Immunology Research.

[52]  Q. Luo,et al.  Diagnostic yield and postoperative mortality associated with surgical lung biopsy for evaluation of interstitial lung diseases: A systematic review and meta-analysis. , 2015, The Journal of thoracic and cardiovascular surgery.

[53]  S. Kudoh,et al.  Association between baseline pulmonary status and interstitial lung disease in patients with non-small-cell lung cancer treated with erlotinib--a cohort study. , 2014, Clinical lung cancer.

[54]  M. Kusumoto,et al.  Consensus statement for the diagnosis and treatment of drug-induced lung injuries. , 2013, Respiratory investigation.

[55]  Shandra L. Protzko,et al.  An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. , 2013, American journal of respiratory and critical care medicine.

[56]  S. Kudoh,et al.  Nested case control study of proteomic biomarkers for interstitial lung disease in Japanese patients with non-small-cell lung cancer treated with erlotinib: a multicenter phase IV study (JO21661). , 2013, Clinical lung cancer.

[57]  A. Adjei,et al.  Understanding, recognizing, and managing toxicities of targeted anticancer therapies , 2013, CA: a cancer journal for clinicians.

[58]  G. N. Norén,et al.  The Development and Evaluation of Triage Algorithms for Early Discovery of Adverse Drug Interactions , 2013, Drug Safety.

[59]  D. Stover,et al.  Organizing pneumonia as a side effect of ipilimumab treatment of melanoma. , 2013, Chest.

[60]  M. Kitaichi,et al.  Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK-positive non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  Charlie Strange,et al.  An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. , 2012, American journal of respiratory and critical care medicine.

[62]  A. Ravaud,et al.  Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. , 2012 .

[63]  S. Kudoh,et al.  Postmarketing Surveillance Study of Erlotinib in Japanese Patients With Non–Small-Cell Lung Cancer (NSCLC): An Interim Analysis of 3488 Patients (POLARSTAR) , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[64]  I. Pedrosa,et al.  Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome. , 2012, European journal of cancer.

[65]  Young Hak Kim,et al.  Prognostic significance of preexisting interstitial lung disease in Japanese patients with small-cell lung cancer. , 2012, Clinical lung cancer.

[66]  E. Chilvers,et al.  Non-infectious pulmonary toxicity of rituximab: a systematic review. , 2012, Rheumatology.

[67]  X. Bosch,et al.  Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. , 2011, Seminars in arthritis and rheumatism.

[68]  Ho Yun Lee,et al.  Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight , 2011, Cancer Chemotherapy and Pharmacology.

[69]  Yusuke Nakamura,et al.  Interstitial lung disease in gefitinib-treated Japanese patients with non-small-cell lung cancer: genome-wide analysis of genetic data. , 2011, Pharmacogenomics.

[70]  Marie C. South,et al.  Proteomic Biomarkers for Acute Interstitial Lung Disease in Gefitinib-Treated Japanese Lung Cancer Patients , 2011, PloS one.

[71]  A. Gemma,et al.  Clarification of clinical features of interstitial lung disease induced by irinotecan based on postmarketing surveillance data and spontaneous reports , 2011, Anti-cancer drugs.

[72]  J. Maroto,et al.  Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  H. Ohmatsu,et al.  Severe Interstitial Lung Disease Associated with Amrubicin Treatment , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[74]  J. Ryu.  Chemotherapy-induced pulmonary toxicity in lung cancer patients. , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[75]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[76]  A. Ravaud,et al.  Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. , 2010, American journal of respiratory and critical care medicine.

[77]  Susanne Hempel,et al.  Meta-analysis: Effect of Interactive Communication Between Collaborating Primary Care Physicians and Specialists , 2010, Annals of Internal Medicine.

[78]  Carlos A. Rabasso,et al.  Interstitial lung disease associated to erlotinib treatment: a case report , 2010, Cases journal.

[79]  K. Kiura,et al.  Comparison of the Incidence and Pattern of Interstitial Lung Disease During Erlotinib and Gefitinib Treatment in Japanese Patients with Non-small Cell Lung Cancer: The Okayama Lung Cancer Study Group Experience , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[80]  H. Kuo,et al.  Erlotinib-associated near-fatal interstitial pneumonitis in a patient with relapsed lung adenocarcinoma. , 2010, Chang Gung medical journal.

[81]  H. Kato,et al.  Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. , 2008, American journal of respiratory and critical care medicine.

[82]  N. Müller,et al.  Fleischner Society: glossary of terms for thoracic imaging. , 2008, Radiology.

[83]  P. Marik,et al.  Pulmonary complications of novel antineoplastic agents for solid tumors. , 2008, Chest.

[84]  M. Kris,et al.  Pulmonary toxicity associated with erlotinib. , 2007, Chest.

[85]  Susan Murray,et al.  Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis? , 2007, American journal of respiratory and critical care medicine.

[86]  B. Vahid,et al.  Erlotinib-associated acute pneumonitis: report of two cases. , 2007, Canadian respiratory journal.

[87]  J. Lafitte,et al.  Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer , 2007, BMC Cancer.

[88]  G. Pond,et al.  Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. , 2006, European journal of cancer.

[89]  M. Fukuoka,et al.  Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  N. Müller,et al.  Drug-induced lung diseases: most common reaction patterns and corresponding high-resolution CT manifestations. , 2006, Seminars in ultrasound, CT, and MR.

[91]  H. Ohmatsu,et al.  First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  K. Matsuo,et al.  Interstitial Lung Disease in Japanese Patients With Non‐Small Cell Lung Cancer Receiving Gefitinib: An Analysis of Risk Factors and Treatment Outcomes in Okayama Lung Cancer Study Group , 2005, Cancer journal.

[93]  Renato Martins,et al.  Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.

[94]  Susan Murray,et al.  Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? , 2004, American journal of respiratory and critical care medicine.

[95]  P. Foucher,et al.  Drug-induced and iatrogenic infiltrative lung disease. , 2004, Clinics in chest medicine.

[96]  P. Foucher,et al.  Interstitial Lung Disease Induced by Drugs and Radiation , 2004, Respiration.

[97]  K. Kiura,et al.  Interstitial lung disease (ILD) during gefitinib treatment in Japanese patients with non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group , 2004 .

[98]  N. Yamamoto,et al.  Interstitial lung diseases (ILD) induced by gefitinib in patients with advanced non-small cell lung cancer (NSCLC): Results of a West Japan Thoracic Oncology Group (WJTOG) epidemiological survey. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[99]  M. Kusumoto,et al.  Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. , 2004, Lung cancer.

[100]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[101]  S. Swensen,et al.  Drug-Induced Lung Disease: A Pragmatic Classification Incorporating HRCT Appearances , 2003, Seminars in respiratory and critical care medicine.

[102]  M. Ebina,et al.  Severe acute interstitial pneumonia and gefitinib , 2003, The Lancet.

[103]  N. Müller,et al.  Drug-induced lung disease: high-resolution CT and histological findings. , 2002, Clinical radiology.

[104]  Paul J. Friedman,et al.  American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors , 2002, American journal of respiratory and critical care medicine.

[105]  J. Erasmus,et al.  High-resolution CT of drug-induced lung disease. , 2002, Radiologic clinics of North America.

[106]  V. Poletti,et al.  Comparison of registries of interstitial lung diseases in three European countries. , 2001, The European respiratory journal. Supplement.

[107]  N. Müller,et al.  Drug-induced lung disease: high-resolution CT findings. , 2000, AJR. American journal of roentgenology.

[108]  P C Goodman,et al.  Pulmonary drug toxicity: radiologic and pathologic manifestations. , 2000, Radiographics : a review publication of the Radiological Society of North America, Inc.

[109]  N. Müller,et al.  Acute interstitial pneumonia: thin-section CT findings in 36 patients. , 1999, Radiology.

[110]  S. Primack,et al.  The spectrum of eosinophilic lung disease: radiologic findings. , 1997, Journal of computer assisted tomography.

[111]  J. Allison,et al.  CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation , 1995, The Journal of experimental medicine.

[112]  T. Honjo,et al.  Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. , 1992, The EMBO journal.

[113]  N. Müller,et al.  High-resolution computed tomography of drug-induced lung disease. , 1992, Clinical radiology.

[114]  E. Rosenow,et al.  Drug-induced pulmonary disease. An update. , 1992, Chest.

[115]  J. Kuhlman.  The role of chest computed tomography in the diagnosis of drug‐related reactions , 1991, Journal of thoracic imaging.

[116]  G. Pietra.  Pathologic mechanisms of drug‐induced lung disorders , 1991, Journal of thoracic imaging.

[117]  C. Taylor.  Diagnostic imaging techniques in the evaluation of drug-induced pulmonary disease. , 1990, Clinics in chest medicine.

[118]  G. Searles,et al.  Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature. , 1987, The Journal of rheumatology.

[119]  R. Matthay,et al.  Drug-induced pulmonary disease. Part 2: Noncytotoxic drugs. , 1986, The American review of respiratory disease.